Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.48 |
| ▸ | MPO | P05164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CHKA | P35790 | 4/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10819382 | 0.83 | KDM4E (0.70) | KDM4ESMN1; SMN2NR1H2MPOALDH1A1 | |
| SCHEMBL14924465 | 0.82 | KDM4E (0.50) | KDM4ESMN1; SMN2NR1H2MPOALDH1A1 | |
| SCHEMBL20680180 | 0.81 | HTR6 (0.49) | KDM4ESMN1; SMN2NR1H2MPOALDH1A1 | |
| SCHEMBL15546497 | 0.81 | CYP2A13 (0.61) | KDM4ESMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL15542251 | 0.81 | NR1H2 (0.67) | KDM4ESMN1; SMN2NR1H2MPOALDH1A1 | |
| SCHEMBL327602 | 0.81 | KDM4E (0.49) | KDM4ESMN1; SMN2NR1H2MPOALDH1A1 | |
| SCHEMBL18753928 | 0.81 | KDM4E (0.64) | KDM4ESMN1; SMN2ALDH1A1POLBTDP1 | |
| SCHEMBL28864320 | 0.80 | NR1H2 (0.70) | KDM4ENR1H2ALDH1A1POLB | |
| SCHEMBL8251581 | 0.79 | CHKA (0.50) | KDM4ESMN1; SMN2NR1H2MPOALDH1A1 | |
| SCHEMBL1394116 | 0.78 | KDM4E (0.54) | KDM4EALDH1A1POLBCHKAHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2875001-B1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | SUNSHINE LAKE PHARMA CO LTD (CN) | 2019-01-09 | — | — | EP | disclosed |
| US-9434695-B2 | Nitrogenous heterocyclic derivatives and their application in drugs | SUNSHINE LAKE PHARMA CO., LTD (CN) | 2016-09-06 | — | — | US | disclosed |
| CN-103570630-B | Nitrogen heterocyclic derivative and the application in medicine thereof | SUNSHINE LAKE PHARMA CO.,LTD. (CN) | 2016-04-20 | — | — | CN | disclosed |
| EP-2875001-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | Sunshine Lake Pharma Co., Ltd. (CN) | 2015-05-27 | — | — | EP | disclosed |
| US-20150087639-A1 | Nitrogenous Heterocyclic Derivatives And Their Application In Drugs | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-03-26 | — | — | US | disclosed |
| WO-2014012360-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087639-A1 | Nitrogenous Heterocyclic Derivatives And Their Application In Drugs | TNNC1, TNNI3, IAPP | KDM4E 4181/4885SMN1; SMN2 18/4885NR1H2 3345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.